Wellness & Beauty PR
Supplement enforcement in 2026: FDA, FTC and ASA data
On 20 October 2026 the FDA finalised the identity and safety sections of its guidance on new dietary ingredient (NDI) notifications. Alongside that, we counted what regulators actually acted on this year. From 1 January to 22 October 2026, the FDA, the US Federal Trade Commission and the UK Advertising Standards Authority took 39 formal actions against supplement companies.
Key finding: 11 of the FDA’s 18 supplement warning letters in 2026 cited disease or drug claims, on their own or alongside other violations. Claims, not just factories, are what gets companies letters.
The FDA’s 18 supplement warning letters, by violation
| Main violation | Letters |
|---|---|
| Disease or drug claims only | 4 |
| Disease or drug claims plus manufacturing (CGMP) violations | 5 |
| Manufacturing (CGMP) violations only | 5 |
| Undeclared drugs found by FDA testing, plus disease or drug claims | 2 |
| New dietary ingredient without adequate safety evidence | 2 |
| Total | 18 |
One of the two new-ingredient letters went to a product marketed as a “GLP-1 biomimetic”: the GLP-1 trend is reaching supplement shelves.
The FTC: claims about mental health and children’s height
The FTC’s four supplement actions this year involved two companies. TruHeight was charged over height-growth claims for supplements marketed to children and teens (complaint and proposed settlement in April, final order in July). Amare Global was charged over claims that its supplements treat depression, anxiety and ADHD (complaint 2 June), and the FTC also moved to hold it in contempt of an earlier order (12 June).
The UK: 17 upheld ASA rulings
The ASA upheld 17 rulings against supplement ads in 2026. They include a 25 March batch of five rulings on women’s hormone supplements making menopause and PCOS claims, and products claiming GLP-1-like effects. In October the ASA also reported that only a small share of ads for supplements aimed at ADHD and autism, and for prostate supplements, complied with the rules.
What changes with the NDI guidance
The final sections explain what identity and safety information the FDA expects in an NDI notification. Two of this year’s letters were about new ingredients where the FDA judged the safety evidence inadequate, in one case after objecting to the company’s notifications. Brands launching products with new ingredients now have clearer expectations to meet.
What this means for supplement brands’ PR
A claim that would get a warning letter on a label will also sink a press release: health journalists check claims against what regulators allow. Our wellness and beauty PR work starts from claims that hold up, and our guide to PR for supplement brands covers how to get coverage without them.
This is a summary of public enforcement records, not legal advice.
Method
- FDA: all 474 warning letters dated 1 Jan – 22 Oct 2026, classified from the letter text. Letters FDA filed under drugs or food are included where they concern products marketed as dietary supplements.
- FTC: every 2026 FTC press release, plus the case pages for candidate actions. Multi-level marketing cases about earnings claims are excluded.
- ASA: all formal rulings published 1 Jan – 22 Oct 2026, filtered by topic and checked by hand.
Frequently asked questions
Why does the FDA send warning letters to supplement companies?
In 2026 the most common reasons were claims that a supplement treats or prevents disease, which makes it an unapproved drug, and manufacturing practice failures. Some letters cited both.
What is a new dietary ingredient notification?
A company must notify the FDA before marketing a supplement with a dietary ingredient that was not sold in the US before 15 October 1994, unless an exemption applies. On 20 October 2026 the FDA finalised the identity and safety information sections of its guidance on these notifications.
Can a supplement claim to work like a GLP-1 drug?
In the UK, the ASA upheld rulings in 2026 against supplements claiming GLP-1-like effects. In the US, the FDA cited a GLP-1-branded supplement over the safety of a new ingredient.
Can I use this data?
Yes. Please cite HealthSpark PR and link to this page.
Sources
- FDA, Warning Letters database.
- Federal Register, NDI Notifications: Identity and Safety Information, Guidance for Industry (20 October 2026).
- FTC press releases on TruHeight (April and July 2026) and Amare Global (June 2026).
- ASA, Rulings, 1 Jan – 22 Oct 2026.
- HealthSpark PR, 2026 health ad enforcement dataset (CSV linked above).